Press-release for stocks for biib

Prices are updated after-hours

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
Published: 2022-10-17 (Crawled : 12:00) - globenewswire.com
IONS | $40.81 -0.24% -0.25% 990K

| -11.76% | O: 0.97% H: 1.62% C: -0.62%
BIIB | $190.55 -0.84% -0.84% 1.5M

| -26.26% | O: 0.54% H: 2.99% C: 1.32%
drug extension application review

| -27.73% | O: 0.0% H: 1.44% C: -1.15%
disease alzheimer ema phase 2 clinical trials trials phase 2b trial conference alzheimer’s alzheimer's disease alzheimer's biomarkers lecanemab

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Published: 2021-10-17 (Crawled : 00:00) - globenewswire.com
BIIB | $190.55 -0.84% -0.84% 1.5M

| -31.62% | O: -2.1% H: 0.03% C: -3.47%
results topline phase 3 als

Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
Published: 2021-01-29 (Crawled : 13:00) - globenewswire.com
BIIB | $190.55 -0.84% -0.84% 1.5M

| -27.15% | O: 9.91% H: 0.66% C: -4.01%
fda license alzheimer application

64%

36%

AGBA | $1.02 155.0% 57.94% 120M

ZCMD | $2.86 108.76% 52.1% 2.3M

INVO | $1.555 104.6% 51.13% 5M

ISPC | $0.437 105.16% 49.53% 37M

WLGS | $0.92 84.0% 45.65% 1.6M

OST | $0.499 21.38% 45.26% 1.9M

XPON | $3.1 60.62% 37.74% 17M

TIRX | $0.7 44.39% 30.74% 58M

BNTC | $6.92 44.17% 30.64% 3.5M

GGE | $0.035 19.86% 29.3% 64M

Save your searches and get alerts when important news are released.